Phaseline

Companies › Alumis

Alumis: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 2 Phase 2, 1 Phase 3; Immunology; next expected readout Sep 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Envudeucitinib (ESK-001)
Oral PROTAC degrader of Ikaros (IKZF1)
IKZF1, TYK2Phase 3Plaque Psoriasis; SLESep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05966480Envudeucitinib (ESK-001)Phase 2SLEImmunologySep 2027
NCT05739435Envudeucitinib (ESK-001)Phase 2Plaque PsoriasisImmunologyDec 2027
NCT06846541Envudeucitinib (ESK-001)Phase 3Plaque PsoriasisImmunologyNov 2028

From the company's SEC filings

Cash and short-term investments of $502m on 2026-06-30; operating cash outflow about $342m a year; runway about 18 months at that burn, to Dec 2027; 2 of 3 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Agreements filed with the SEC (item 1.01), last two years

Targets

IKZF1 (1) TYK2 (1)

Companies with the same targets

Bristol-Myers Squibb AbbVie Sun Pharmaceutical Industries Alfasigma Takeda Incyte LEO Pharma Eisai InventisBio Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical

Companies built like this

Savara Alfasigma Quoin Pharmaceuticals Pharvaris Netherlands AUG Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.